header logo image


Page 725«..1020..724725726727..730740..»

Changed landscape of biotech sector, fiercely committed to India, says Department of Biotechnology secretary Dr Renu Swarup – The Indian Express

January 30th, 2020 3:45 pm

Written by Anuradha Mascarenhas | Pune | Published: January 29, 2020 5:20:12 am Dr M K Bhan

Hailing him as the strong pillar on which the Department of Biotechnology (DBT) stood today, secretary Dr Renu Swarup said noted paediatrician and former DBT secretary Dr M K Bhan, who died on January 26, changed the landscape of the biotechnology sector and was among those scientists who had been able to fulfil the dream of introducing a rotavirus vaccine, now part of the universal immunisation programme. Swarup worked closely with Dr Bhan for over a decade.

Dr Bhan pioneered the first indigenously developed rotavirus vaccine and the highest tribute to him would be to take forward his legacy, Dr Swarup said, adding that he was a visionary and his death had left a void that will never get filled.

The rotavirus vaccine was developed from scratch and the government introduced it in the public health programme from 2016.

Generous and passionate about building up young people, Dr Bhan was fiercely committed to our country and its science, but gentle in his approach to individuals and rigorous in his approach to institutions. Dr Bhan was unique and special, Prof Gagandeep Kang, executive director of Translational Health Science and Technology Institute, Faridabad, told The Indian Express.

Prof Chittaranjan Yajnik, noted diabetologist and director of the diabetes unit at KEM hospital in Pune said his death was a massive loss to Indian science. His legacy will guide us in solving problems, said Prof Yajnik, who was his close friend.

Prof Yajnik added that he was a visionary scientist who handled science, its translation and management seamlessly. Dr Bhan was instrumental in promoting new biotechnology institutes in different parts of the country and involving scientists of multiple specialties to interact with each other under the umbrella of biotechnology.

We are now observing the fruits of this approach. He was instrumental in setting up the vaccine field trial unit at KEM hospital, which has contributed significantly to rotavirus research and related studies, Prof Yajnik said.

Dr Bhan was my mentor; as a young trainee gastroenterologist visiting AIIMS, he inspired us to inculcate a systematic approach to clinical problems and as a teacher of epidemiology he shared his belief that public health research was the need of the hour, said Dr Ashish Bawdekar, consultant paediatric gastroenterologist at KEM hospital.

Dr Bawdekar further talked of his close involvement with Dr Bhan, who was the DBT secretary during the development of the Indian rotavirus vaccine.

He was extremely nationalistic and felt Indian scientists were as good as others in the world and would not accept any interference from foreign funders. It was unbelievable what he could foresee and then, more importantly, do something about it, he said.

Dr Sanjay Juvekar, head of the Vadu Rural Health Programme said their team will cherish the experience shared with Dr Bhan on the rotavirus vaccine research,

He was in favour of translational research that could yield results with immediate benefits to the public. Apart from his immense contribution towards the indigenous rotavirus vaccine, he was also instrumental in the identification of zinc deficiency as the cause behind several abnormalities observed in children, said Dr Manoj Kumar Bhat, director of National Centre for Cell Science (NCCS).

Senior scientist at NCCS, Dr Yogesh Shouche, said during his tenure, Dr Bhan came up with several new initiatives not only in health but also in other sectors like agriculture and food processing.

For all the latest Pune News, download Indian Express App

Read the rest here:
Changed landscape of biotech sector, fiercely committed to India, says Department of Biotechnology secretary Dr Renu Swarup - The Indian Express

Read More...

Europe’s guardian of stem cells and hopes, real and unrealistic – INQUIRER.net

January 30th, 2020 3:44 pm

Submerged in liquid nitrogen vapor at a temperature of minus 175 degrees Celsius, hundreds of thousands of stem cells from all over Europe bide their time in large steel barrels on the outskirts of Warsaw.

Present in blood drawn from the umbilical cord of a newborn baby, stem cells can help cure serious blood-related illnesses like leukemias and lymphomas, as well as genetic conditions and immune system deficits.

Polish umbilical cord blood bank PBKM/FamiCord became the industrys leader in Europe after Swiss firm Cryo-Save went bankrupt early last year.

It is also the fifth largest in the world, according to its management, after two companies in the United States, a Chinese firm and one based in Singapore.

Since the first cord blood transplant was performed in France in 1988, the sector has significantly progressed, fuelling hopes.

Health insurance

Mum-of-two Teresa Przeborowska has firsthand experience.

At five years old, her son Michal was diagnosed with lymphoblastic leukemia and needed a bone marrow transplant, the entrepreneur from northern Poland said.

The most compatible donor was his younger sister, Magdalena.

When she was born, her parents had a bag of her cord blood stored at PBKM.

More than three years later, doctors injected his sisters stem cells into Michals bloodstream.

It was not quite enough for Michals needs but nicely supplemented harvested bone marrow.

As a result, Michal, who is nine, is now flourishing, both intellectually and physically, his mum told AFP.

A cord blood transplant has become an alternative to a bone marrow transplant when there is no donor available, with a lower risk of complications.

Stem cells taken from umbilical cord blood are like those taken from bone marrow, capable of producing all blood cells: red cells, platelets and immune system cells.

When used, stem cells are first concentrated, then injected into the patient. Once transfused, they produce new cells of every kind.

At the PBKM laboratory, each container holds up to 10,000 blood bags Safe and secure, they wait to be used in the future, its head, Krzysztof Machaj, said.

The bank holds around 440,000 samples, not including those from Cryo-Save, he said.

If the need arises, the blood will be ready to use without the whole process of looking for a compatible donor and running blood tests, the biologist told AFP.

For families who have paid an initial nearly 600 euros (around P34,000) and then an annual 120 euros (around P7,000) to have the blood taken from their newborns umbilical cords preserved for around 20 years, it is a kind of health insurance promising faster and more effective treatment if illness strikes.

But researchers also warn against unrealistic expectations.

Beauty products

Hematologist Wieslaw Jedrzejczak, a bone marrow pioneer in Poland, describes promoters of the treatment as sellers of hope, who make promises that are either impossible to realize in the near future or downright impossible to realize at all for biological reasons.

He compares them to makers of beauty products who swear their cream will rejuvenate the client by 20 years.

Various research is being done on the possibility of using the stem cells to treat other diseases, notably nervous disorders. But the EuroStemCell scientist network warns that the research is not yet conclusive.

There is a list of almost 80 diseases for which stem cells could prove beneficial, U.S. hematologist Roger Mrowiec, who heads the clinical laboratory of the cord blood program Vitalant in New Jersey, told AFP.

But given the present state of medicine, they are effective only for around a dozen of them, like leukemia or cerebral palsy, he said.

Its not true, as its written sometimes, that we can already use them to fight Parkinsons disease or Alzheimers disease or diabetes.

EuroStemCell also cautions against private blood banks that advertise services to parents suggesting they should pay to freeze their childs cord blood in case its needed later in life.

Studies show it is highly unlikely that the cord blood will ever be used for their child, the network said.

It also pointed out that there could be a risk of the childs cells not being useable anyway without reintroducing the same illness.

Some countries, such as Belgium and France, are cautious and ban the storage of cord blood for private purposes. Most E.U. countries however permit it while imposing strict controls.

Rapid growth

In the early 2000s, Swiss company Cryo-Save enjoyed rapid growth.

Greeks, Hungarians, Italians, Spaniards and Swiss stored blood from their newborns with the company for 20 years on payment of 2,500 euros (around P140,000) upfront.

When the firm was forced to close in early 2019, clients were left wondering where their stem cells would end up.

Under a kind of back-up agreement, the samples of some 250,000 European families were transferred for storage at PBKM.

The Polish firm, founded in 2002 with 2 million zlotys (around P26 million), has also grown quickly.

Present under the FamiCord brand in several countries, PBKM has some 35% of the European market, excluding Cryo-Save assets.

Over the last 15 months, outside investors have contributed 63 million euros to the firm, PBKMs chief executive Jakub Baran told AFP.

But the company has not escaped controversy: the Polityka weekly recently published a critical investigative report on several private clinics that offer what was described as expensive treatment involving stem cells held by PBKM.IB/JB

RELATED STORIES:

2019: The year gene therapy came of age

Landmark trial finds stem cell treatment reduces disability for those with multiple sclerosis

Link:
Europe's guardian of stem cells and hopes, real and unrealistic - INQUIRER.net

Read More...

Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD) -…

January 30th, 2020 3:44 pm

Early Clinical Data Support ex vivo Hematopoietic Stem Cell Gene Therapy as a Potentially Promising Treatment Option for X-CGD

BOSTON and LONDON, Jan. 29, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a global gene therapy leader, today announced that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for OTL-102, the companys ex vivo autologous hematopoietic stem cell (HSC) gene therapy being investigated for the treatment of X-linked chronic granulomatous disease (X-CGD). The FDA may grant orphan designation to drugs and biologics intended to treat a rare disease or condition affecting fewer than 200,000 persons in the U.S.

We are pleased to have received this orphan drug designation from the FDA, which recognizes the potential of OTL-102 to address a rare population of patients with X-CGD, a life-threatening disease with a critical unmet need, said Anne Dupraz-Poiseau, Ph.D., chief regulatory officer at Orchard. We are encouraged by the clinical data published to date and are eager to advance OTL-102 development as quickly as possible for patients with X-CGD.

Orphan designation qualifies a company for certain benefits, including financial incentives to support clinical development and the potential for seven years of market exclusivity in the U.S. upon regulatory approval.

Early academic clinical trial data for OTL-102 that was recently published in Nature Medicine demonstrates that ex vivo autologous HSC gene therapy may be a promising approach for the treatment of X-CGD. The letter, which wasled by researchers at the University of California, Los Angeles (UCLA)including Donald B. Kohn, M.D., one of the study's lead investigators and professor of microbiology, immunology and molecular genetics at UCLA and Great Ormond Street Hospital (UK), provides an analysis of safety and efficacy outcomes in nine severely affected patients with X-CGD. At 12 months post-treatment, six of seven surviving patients, all of whom were adults or late adolescents, exceeded the minimum threshold hypothesized in published literature to demonstrate potential clinical benefit, defined as 10% functioning, oxidase-positive neutrophils in circulation and have discontinued preventive antibiotics.1

As previously reported, two pediatric patients died within three months of treatment from complications deemed by the investigators and independent data and safety monitoring board to be related to pre-existing comorbidities due to advanced disease progression and unrelated to OTL-102. Investigators are planning to enroll additional pediatric patients in 2020 to assess outcomes in this patient population. In addition, there is work underway to improve the efficiency of the drug product manufacturing process prior to initiating a registrational study.

Patients with X-CGD experience significantly reduced quality and length of life, and currently must take daily medications that do not eliminate the risk of fatal infections, said Adrian Thrasher, Ph.D., M.D., one of the studys lead investigators and professor of pediatric immunology and Wellcome Trust Principal Research Fellow at UCL Great Ormond Street Institute of Child Health in London. These data demonstrate that OTL-102 has the potential to become a transformative new treatment option for patients with X-CGD with the evaluation of longer follow up and more patients.

About X-CGDX-linked chronic granulomatous disease (X-CGD) is a rare, life-threatening, inherited disease of the immune system caused by mutations in the cytochrome B-245 beta chain (CYBB) gene encoding the gp91phox subunit of phagocytic NADPH oxidase. Because of this genetic defect, phagocytes, or white blood cells, of X-CGD patients are unable to kill bacteria and fungi, leading to chronic, severe infections. The main clinical manifestations of X-CGD are pyoderma, a type of skin infection; pneumonia; colitis; lymphadenitis, an infection of the lymph nodes; brain, lung and liver abscesses; and osteomyelitis, an infection of the bone. Patients with X-CGD typically start to develop infections in the first decade of life, and an estimated 40 percent of patients die by the age of 35.2 The incidence of X-CGD is currently estimated at between 1 in 100,000 and 1 in 400,000 male births.

Story continues

About OTL-102OTL-102 is an ex vivo autologous hematopoietic stem cell gene therapy being studied for the treatment of X-CGD. The studies are supported by multiple institutions including the California Institute of Regenerative Medicine, the Gene Therapy Resource Program from the National Heart, Lung, and Blood Institute, the National Institute of Allergy and Infectious Diseases Intramural Program, the Wellcome Trust and the National Institute for Health Research Biomedical Research Centres at Great Ormond Street Hospital for Children NHS Foundation Trust, University College London Hospitals NHS Foundation Trust and University College London. Preclinical and clinical development of OTL-102 had originally been initiated by Genethon (Evry, France) and funded by an EU framework 7 funded consortium, NET4CGD, before being licensed to Orchard.

About OrchardOrchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically-modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. The company has one of the deepest gene therapy product candidate pipelines in the industry and is advancing seven clinical-stage programs across multiple therapeutic areas, including inherited neurometabolic disorders, primary immune deficiencies and blood disorders, where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

Forward-Looking StatementsThis press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as anticipates, believes, expects, plans, intends, projects, and future or similar expressions that are intended to identify forward-looking statements. Forward-looking statements include express or implied statements relating to, among other things, the therapeutic potential of Orchards product candidates, including the product candidate or candidates referred to in this release, Orchards expectations regarding the timing of regulatory submissions for approval of its product candidates, including the product candidate or candidates referred to in this release, the timing of interactions with regulators and regulatory submissions related to ongoing and new clinical trials for its product candidates, the timing of announcement of clinical data for its product candidates and the likelihood that such data will be positive and support further clinical development and regulatory approval of these product candidates, and the likelihood of approval of such product candidates by the applicable regulatory authorities. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, without limitation: the risk that any one or more of Orchards product candidates, including the product candidate or candidates referred to in this release, will not be successfully developed or commercialized, the risk of cessation or delay of any of Orchards ongoing or planned clinical trials, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates,the delay of any of Orchards regulatory submissions, the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates, the receipt of restricted marketing approvals, and the risk of delays in Orchards ability to commercialize its product candidates, if approved. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards annual report on Form 20-F for the year ended December 31, 2018, as filed with the U.S. Securities and Exchange Commission (SEC) on March 22, 2019, as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

References1Kang et al. Blood. 2010;115(4):783-912van den Berget al. PLoS One. 2009;4(4):e5234

Contacts

InvestorsRenee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com

MediaMolly CameronManager, Corporate Communications+1 978-339-3378media@orchard-tx.com

See more here:
Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD) -...

Read More...

Dad launches appeal in memory of Eimear – Belfast Media Group

January 30th, 2020 3:44 pm

By Michael Jackson

THE father of a young West Belfast cancer battler, who passed away last year, has helped launch the Donuts for Donors appeal, the Norths first ever Stem Cell Donation Awareness Day.Sen Smyth, whose daughter Eimear Gooderman (ne Smyth) died on the 27th of June 2019, was joined by the Lord Mayor Danny Baker for the appeal launch a City Hall on Tuesday.In September 2016, Eimear was diagnosed with stage two Hodgkins Lymphoma, a type of blood cancer.After finding a stem cell donor match, Eimear underwent a transplant in November 2018, but sadly passed away following complications.Throughout her illness, the Coolnasilla woman fought to raise awareness of stem cell donation alongside her family, who established the Eimears Wish campaign to continue her work.Speaking to the Andersonstown News, Sen explained the idea behind the Donuts for Donors appeal, which will take place next Friday.The most important thing here is getting the message out that we need people to become stem cell donor and organ donors, he said.We want our politicians to fall into line with England and Wales and bring in the soft opt out where everybody is a donor, and if you dont want to be a donor then you need to opt out.This is our first ever Northern Ireland-wide Stem Cell Donation awareness day and Eimear loved donuts and coffee, so we married the two together.We have raised three or four thousand pounds for charity since Eimear died maybe more and we just dont ask people for money. We try to organize events to give people a reason to put their hands in their pockets, so we thought why dont we do Donuts for Donors get them to buy a donut, get them to have a coffee morning in their workplace.The money is going to fantastic charities; Action Cancer, Friends of the Cancer Centre and the Anthony Nolan Trust. That way were hoping to raise a few pound.Our percentage of donors is very low, so its also about getting people talking about and become aware of it.To mark the occasion on Friday, January 31, City Hall will also be lit up pink, which was Eimears favourite colour.Local businesses and schools will also be involved including West Belfasts All Saints College and St Louises Comprehensive College.Speaking ahead the event, Councillor Baker encouraged everyone to get the kettle on and pick up a donut to help raise much-needed funds and awareness of stem cell donation.This is a very important initiative which is helping to shine a spotlight on the important topic of stem cell donation and organ donation generally, he said.The team at Eimears Wish have worked tirelessly to keep the spirit of Eimear alive and continue her great work by making stem cell donation an important topic of conversation.On Friday 31 January I will be hosting a special coffee morning in the Parlour for people and families affected by stem cell transplants and Im calling on everyone across the city to follow suit and get involved for this great cause.

Please follow and like us:

Continue reading here:
Dad launches appeal in memory of Eimear - Belfast Media Group

Read More...

Dodge Elementary rallies around beloved therapy dog – Amherst Bee

January 30th, 2020 3:44 pm

Students at Dodge Elementary School hold up colored portraits of Yeti, the schools therapy dog, in the classroom.

Dodge Elementary students have been missing one of their favorite faculty members; Yeti the therapy dog has been absent as he heals from hip dysplasia complications.

Dan Steck, head custodian at Dodge Elementary, rescued Yeti from a puppy mill near Lancaster, Pennsylvania, on March 19, 2016. Little did he know then that soon, Yeti would become a certified therapy dog, complete with his own office at Dodge.

Steck originally rescued Yeti in the hope that a sibling would calm down his other rambunctious malamute, Luna. While the adoption didnt quite have the desired effect, Steck soon realized that Yeti was special he was kind, gentle and always happy, a perfect candidate to become a therapy dog.

Since his certification through the SPCAs Paws for Love program, Yeti has worked at Dodge, a friendly face for struggling children or a non-judgmental listener for children practicing their reading. Steck said that teachers and students make requests to have Yeti in their classrooms left and right.

They adore Yeti, said Dodge principal Charlie Smilinich. Its cool to see how a dog can impact students. Its very unique. Hes been here for two years and has built a relationship with everyone. Hes a Dodger. The dog has his own office.

Yeti is what his owners call a tripaw, meaning that one of his legs was amputated due to a neglected infection he sustained under the care of his previous owners. As a result of walking on only three legs, the 4-year-old Alaskan malamute struggles with hip dysplasia.

Originally, Yeti was prescribed hydrotherapy, though he struggled to keep up with the treatment and would come home exhausted. Now, veterinarians are considering acupuncture, stem cell treatment or even a total hip replacement.

Hopefully, hell live a long life, but hes got some real challenges already, said Steck. At age 4, hes nowhere near as playful as he was, and he sleeps a lot. Eventually, he may even need a wheelchair.

Stecks family has dutifully supported Yeti through all of his medical trials, but the bills are racking up quickly. A wheelchair alone would cost them between $1,200 and $1,500.

To help with the costs, the Stecks have a GoFundMe page where they provide medical updates and receive encouraging messages from the elementary students.

To support their beloved therapy dog, Dodge students and the surrounding community have contributed $3,845 thus far, with a goal of $10,000. All of the money raised goes directly into an account at Amherst Small Animal Hospital.

To support the GoFundMe campaign, visit http://www.gofundme.com and search for Throw Kindness Around Like Confetti For Yeti.

To learn more about Yeti and his work at Dodge, search for Yeti Steck on Facebook.

View post:
Dodge Elementary rallies around beloved therapy dog - Amherst Bee

Read More...

Five Biotechs Poised to Advance Their Rare Disease Programs in 2020 – BioBuzz

January 30th, 2020 3:44 pm

February is Rare Disease Awareness Month, a month-long celebration focused on the suffering and triumphs of patients and their families stricken by rare diseases culminating on February 29th International Rare Disease Day. The rapidly developing cell and gene therapy fields in recent years have led to a rare disease R&D boom of sorts, with an estimated 800 rare disease-focused clinical development projects currently in process. The biotech industry sees a new window for improving rare disease patients lives and potentially curing rare diseases that impact one in ten American and an estimated 400 million people globally.

The Biohealth Capital Region (BHCR) is at the leading edge of the rare disease market with companies like American Gene Technologies, REGENXBIO, Cerecor, Asklepion Pharmaceuticals, Lediant, and others advancing their pipelines towards rare disease treatments and cures. The regions robust rare disease sector also includes a host of companies that support rare disease research and development like Jeeva Informatics, GeneDx, Aperiomics and HemoShere among others. In short, the portfolio of rare disease companies and growing support ecosystems make the BHCR a global hub for rare disease R&D.

With Maryland already housing the largest number of Centers of Excellence for the rare disease community, the world travels to us. Roughly speaking, 50% of rare disease patients are children who will never see their tenth birthday and we need this number to change. Currently, Maryland is on the radar to be the next top biotech state and as a mother of two rare disease patients, there is zero time to wait, stated Lydia Seiders, an independent global strategic advisor for the rare disease community and volunteer state ambassador for the National Organization for Rare Disorders (NORD) Maryland Rare Action Network.

Every biotech investing in and pursuing more effective rare disease treatments and potential cures understands Seiders urgency. Lets take a look at some of the leading companies in the BHCR and what we might expect in 2020 from the rare disease programs in their pipelines.

Here is a snapshot of five leading companies and their rare disease pipelines.

American Gene Technologies is a cell and gene therapy company that utilizes a proprietary lentiviral platform to develop potential treatments for liver cancer, Phenylketonuria (PKU), HIV and inherited genetic disorders. AGTs novel lentiviral platform has enabled the company to develop, test and bank thousands of lentiviral vectors, which can then be matched to develop treatments for new target diseases, including orphan/rare diseases like PKU as well as diseases with larger patient populations.

PKU is an inherited, monogenetic disease that causes excess accumulation of the amino acid phenylalanine (Phe), which can reach toxic levels in the blood without strict dietary control. Children born with PKU (PKU occurs in approximately 1 in every 13,500 births) can suffer brain and organ defects if not placed on a special diet and adults can suffer neuropsychiatric impairments including poor behavioral restraint and limited executive function with a high risk of self-injury.

AGT is committed to curing PKU via its proprietary lentiviral platform. The company received FDA Orphan Drug Designation in 2018 and is progressing its PKU therapy toward the clinic.

REGENXBIO is a leading clinical-stage biotechnology company developing gene therapies for retinal, neurodegenerative and metabolic diseases. The companys proprietary NAV Platform, which was invented to discover next-generation adeno-associated viral (AAV) vectors to propel the discovery of new therapies across a wide range of disease areas, including rare/orphan diseases. REGENXBIO has exclusive rights to more than 100 novel AAV vectors and more than 100 patents and patent applications for AAV vectors worldwide.

REGENXBIO currently has 13 clinical-stage products and has 20 partnered programs. One of their out-licensed programs delivered an important milestone for the company, and for the rare disease community. The FDA approval of Avexis ZOLGENSMA, which was developed from REGENXBIOs NAV Technology Platform, became the first cure for spinal muscular atrophy (SMA) and a monumental triumph of the use of gene therapy for the rare disease field. SMA is a fatal childhood neuromuscular disease caused by a mutation in a single gene.

The companys pipeline includes several rare disease candidates.

RGX-121 is a product candidate for Hunter Syndrome (Mucopolysaccharidosis Type II), which is a rare, X-linked recessive disease that causes developmental delay and developmental regression in children. In December 2019, the company announced that it had successfully advanced the clinical safety and efficacy testing into the second cohort of patients at a higher dosage level. Interim data on the second cohort should be released by approximately mid-2020. The first cohort of dosed patients resulted in positive safety and efficacy outcomes, including a meaningful and sustained reduction in heparan sulfate suggesting that the gene therapy can potentially restore intracellular activity of the I2S enzyme, as well as the early signs of neurocognitive stability that have been observed, stated Steve Pakola, M.D., Chief Medical Officer of REGENXBIO.

RGX 501 is a therapy being developed for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH), which impacts approximately 11,000 patients globally.

REGENXBIO previously announced the completed dosing of an expanded Cohort 2 in Phase I/II trial of RGX-501 including steroid prophylaxis. Per protocol, patients received at least a 13-week steroid treatment. No serious adverse effects or significant elevations in liver enzyme levels were reported in the expanded Cohort 2. REGENXBIO plans to assess low-density lipoprotein (LDL-C) levels in the expanded Cohort 2 after all patients have completed their steroid treatment and expects to provide interim data in the first half of 2020.

REGENEXBIO is also working to advance RGX-181, which received FDA Rare Pediatric Disease and Orphan Drug Designations as a treatment candidate for late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, one of the most common forms of Batten disease. The company anticipates submitting an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) in the second half of 2020 for RGX-181 to enable initiation of a first-in-human clinical trial for children with CLN2 disease.

RGX-111 is REGENEXBIOs potential treatment for another rare disease called Mucopolysaccharidosis Type I (MPS I), a rare, recessive genetic disease that can cause hydrocephalus, spinal cord compression and cognitive impairment. Recruitment, screening, and additional site activations are ongoing in Phase I clinical trials evaluating RGX-111 for the treatment of MPS I. RGX-111 has received orphan drug products, rare pediatric disease and Fast Track designation from the FDA. A program update will be available in the second half of 2020.

REGENXBIOs pipeline is representative of the balanced approach many bioscience companies strive for with a focus on rare disease and potential blockbuster treatments (WET AMD).

Cerecor, Inc. is a publicly-traded biotechnology company focused on developing innovative therapies for Orphan Diseases and ultra-rare pediatric diseases. Founded in 2011, the company has brought numerous prescription medicines, prescription medical devices, and dietary supplement products to the market. Cerecors pipeline includes a host of rare disease treatments in the early stages of development.

Its leading pediatric treatment is CERC-801, an ultra-pure oral formulation of D-galactose currently in development for the treatment of phosphoglucomutase 1 (PGM1) deficiency, also known as PGM1-CDG, which is an inherited genetic disorder with wide-ranging symptoms. This potential treatment is in Phase I clinical trials and is a pediatric program with an expedited 505(b)(2) pathway designation.

Other pediatric rare diseases being targeted by Cerecor include the rare, congenital disorder MPI-CDG, which is in Phase I pediatric trials with an expedited 505(b)(2) pathway designation;Leukocyte Adhesion Deficiency Type II (LADII), also known as SLC35C1-CDG, which is in its IND-enabling phase; and the ultra-rare mitochondrial DNA depletion syndrome (MDS), also known as Deoxyguanosine Kinase (DGUOK) deficiency, which is also in the IND-enabling phase.

Asklepion Pharmaceuticals is a biopharmaceutical company that is exclusively focused on rare disease therapy development, specifically for rare pediatric diseases without viable treatments. The company has shifted its focus exclusively to pediatric rare disease in recent years. Asklepion was founded in 2006 in an effort to commercialize a 15-year academic program focused on developing cholic acid for inborn errors of bile acid metabolism, which is a rare genetic disorder.

Its leading therapy candidate is for acute lung injury induced by cardiopulmonary bypass surgery (CBP), which recently completed Phase III clinical trial enrollment in July 2019. Cardiopulmonary bypass surgery can damage lung tissue and blood vessels, which can lead to significant postoperative problems. Asklepions treatment is unique in that it is preventative rather than remedial. By intravenously administering the protein building block L-Citrulline pre-surgery, Asklepion believes that postoperative complications caused by CBP. The treatment received FDA Orphan Drug Designation in 2017. The company is also starting a clinical trial for Sickle cell disease (acute setting) in Q2/Q3 of 2020.

For more than three decades, iterations of the company now known as Leadiant Biosciences has displayed an unwavering commitment to treating and helping ADA-SCID patients and their families. Bubble Boy Diseaseor adenosine deaminase deficiency-severe combined immunodeficiency (ADA-SCID)is an ultra-rare, inherited autosomal metabolic disorder that severely compromises the immune system and can be fatal if untreated.

In October 2018, Leadiant Biosciences, formerly known as Sigma-Tau Pharmaceuticals, received FDA approval for Revcovi, which delivers improved treatment for patients living with ADA-SCID. Approximately 1 in 200,000 to 1,000,000 newborns are impacted worldwide, representing about 15% of all SCID cases (Source: NIH). As an ultra-rare disease, the patient population is minuscule: Leadiant currently treats 35 ADA-SCID patients in the U.S. and seven in Canada.

Headquartered in Gaithersburg, Maryland, Leadiants roots run deep in the treatment of rare and ultra-rare diseases. Leadiant Biosciences, Inc. is a subsidiary of Leadiant S.p.A., which traces its roots back to Sigma-Tau, a family-owned pharmaceutical company founded in Italy by Emilio and Dr. Claudio Cavazza in 1957. Sigma-Tau Pharmaceuticals was a rare disease treatment pioneer, receiving the fourth orphan drug designation ever in 1984.

Today, Leadiants sole focus is on researching, developing and distributing novel treatments for patients afflicted with some of the rarest diseases in the world. Revcovis recent FDA approval for the treatment of ADA-SCID gives Leadiant eight rare disease products on the North American (U.S. and Canada) market. With a deep commitment to advancing a diverse pipeline of new drugs and therapeutic candidates, Leadiant has seven clinical-stage programs in their pipeline. The two programs in phase III trials include LB101 for the treatment of Cerebrotendinous Xanthomatosis (CTX), and LB301 for the treatment of GNE Myopathy.

There are several other rare disease-focused BHCR companies ready to emerge. Elixirgen Therapeutics of Baltimore, MD is a biotechnology company seeking cures through stem cell biology. Its pipeline currently has four rare disease therapies in its pipeline, all of which are in the early stages of development. The company recently announced a $4M Series A round. Another Baltimore-based biotech, Abri Science, recently launched in September of 2019. Abri Science is focused on developing treatments for PKU with licensed technology. Since its launch, Abri Science has been awarded a $225,000 Small Business Technology Transfer (STTR) Phase I grant from the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

The BHCR is rapidly becoming a global hub for rare disease drug development. A host of BHCR companies, including many cell and gene therapy companies, have made rare disease drug development a key component of their pipeline strategies.

BioBuzz will be featuring rare disease stories throughout Rare Disease Awareness month. And well be keeping close tabs on these rare-disease focused companies as we move deeper into 2020.

Check back in for the latest news and developments.

Steve has over 20 years experience in copywriting, developing brand messaging and creating marketing strategies across a wide range of industries, including the biopharmaceutical, senior living, commercial real estate, IT and renewable energy sectors, among others. He is currently the Principal/Owner of StoryCore, a Frederick, Maryland-based content creation and execution consultancy focused on telling the unique stories of Maryland organizations.

Continue reading here:
Five Biotechs Poised to Advance Their Rare Disease Programs in 2020 - BioBuzz

Read More...

20 Markets to lookout for in 2020 – Expedition 99

January 30th, 2020 3:44 pm

Insight industry exhibits the potential to reveal major business events that impart most relevant insights and holds a strong influence on business communities. There have been notable trends in 2019 as the global insights industry crossed USD 45bn and still continues to raise the bar in the coming years.

Going forward, the market research industry continues to exhibit data insights leading to maximize revenue share for companies that are willing to conduct or outsource market research activities.

Dataintelo A leading market research and consulting company published a list of 20 markets to look for in 2020.

The surgical robots industry is expected to cross USD 25bn in the next five years as per findings by a market research report as there will be a huge demand for automation across the healthcare sector as automation is poised for complex procedures. Moreover, non-invasive surgeries are becoming a common trend for geriatric population with minimal surgical complications. It is also anticipated that surgical robots can help in reducing surgery costs and will gain a high popularity all across the healthcare and medical domain. At present, nanobots are employed for the treatment of arteries and catheter-based robots reveal better operative techniques for cardiac surgeries. North America is the leading market for surgical robots, says the report and it will continue to have a strong influence on the global market.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=11502&license_type=Single%20User

The telemedicine industry is expected to cross USD 22bn in the next five years attributing to rise in consultation costs for healthcare and pharmaceutical followed by treatment for chronic diseases. With the advent of technological innovations and availability of healthcare services, telemedicine market is expected to take a high leap in the near future. The telemedicine features in reducing patient visits to hospitals and clinics and simultaneously reducing the burden on hospital infrastructure. For instance, in the U.S. market telemedicine proves effective for cost-controlling in diabetic patients. Various telecare programs have already gained momentum and witness a high adoption. With the growing interest of consumers in mobile health, telemedicine applications are likely to hold a strong influence in the years to come.Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=602&license_type=Single%20User

The defibrillator market is anticipated to witness a rise in revenue share by USD 9.5bn in the near future driven by a huge rise in cases of cardiac arrests. Both, developed and developing nations are now emphasizing on strengthening public infrastructure by offering emergency medical services and also offer a high awareness on cardiac health. Government norms and spending by major vendors is playing a crucial role in building future opportunities. In addition, use of wearable defibrillators is the latest trend witnessed as a healthcare application that augments the chance of survival in case of severe cardiac arrests by alarming the user even before it occurs. China, India, Japan and other markets within Asia Pacific are adopting to a robust healthcare infrastructure resulting in patient safety.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=31618&license_type=Single%20User

The halitosis market witnessed a huge revenue share in 2019 accounting for USD 8bn. Surge in cases of halitosis is expected to widen the market scope. In a recent study conducted by dental institute, middle-aged people suffer from bad breath problems as a result of accumulation of oral germs and bad cavity. Alone in the United States, more than 70% population annually spends around USD 15bn on oral care and hygiene products to counter bad breath problems. Consumption of tobacco and alcohol have been major drivers for developing oral care problems within a vast population. It is also estimated that there will be an upsurge in the consumption rate in the next three years. Hence, Asia Pacific witness a significant rise in the treatment for halitosis treatment.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=48225&license_type=Single%20User

The cancer stem cell therapeutics market is an emerging one which is expected to bypass USD 150mn in the next five years. Major trends such as rise in awareness and use of advanced genome cell analysis methods have a strong influence the market for cancer stem cell therapeutics. Additionally, Asia Pacific countries like Japan and South Korea are now offering novel opportunities in the line of stem cell therapeutics. Regulatory guidelines and policies are undergoing several revisions for effective development of commercial market. Apart, clinical trials for stem cells validate the potency of stem-cell based products. For instance, there have been several trials undertaken by leading clinical institutes in China such as Xuzhou Medical University and the Affiliated Hospital of Academy of Military Medical Sciences.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=99773&license_type=Single%20User

Artificial Intelligence (AI) is all set to reform the agriculture industry and with this the global market for precision farming market is expected to witness a growth of USD 12bn in the next five years. According to market research experts, AI techniques such as farm robots, data mining and use of computational analysis for seasoned crops will be highly witnessed, Agriculture will therefore be a data-driven industry soon. In fact, the use of Internet of things (IoT) and advanced analytics is widely witnessed in several parts of developed countries. Adoption of UAVs, drones, irrigation controllers and steering systems is expected to gain a high momentum by mid 2020 which is expected to accelerate the proliferation of AI in agriculture. With this, sustainability and productive issues in farming can be confronted with adequate technological resources says a market research report.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=52811&license_type=Single%20User

Automation continues to induce a high interest in the medical industry and automated dispensing units are gaining a huge popularity. The revenue share is expected to sum at USD 1.8bn by 2021 attributing to the ongoing technological innovations and government norms. Automated dispensers find notable uses resulting to minimize medication errors and improve safety processes of healthcare. Healthcare management systems are adopting automated dispensers for effective drug management. Globally, North America market is anticipated to have a strong influence in the international market with concerns for patient health and safety. On the other hand, Asia Pacific witness a rise in geriatric population with immediate medical attention and crucial developments on the infrastructural front.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=82617&license_type=Single%20User

Manufacturing and production sectors are undergoing automation processes and it is likely that automated jobs will be soon a major trend. With the anticipation for the revenue share to cross USD 90bn in the next three years, the demand for high pressure processing equipment will witness huge a significance all over the food and beverage industry. Consumer demand for processed food and growing emphasis on food safety along with adoption of innovation fuels the market growth. Emerging economies such as Latin America and Brazil represent major opportunities for futuristic growth. Chocolate and confectionery processing units represent the largest share in the high pressure processing equipment market. Asia Pacific holds a major accountability thus representing the largest share. Widening scope of urbanization and demand for modern methods of food production are major drivers.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=87718&license_type=Single%20User

Eco-friendly initiatives for consumables and stylish trends of bio-based materials in food industry is globally evident. Government norms and policies followed by ban on plastic products in the food industry highlights the shift from traditional to eco-friendly approach. For instance, paper straws have a huge impact on the market attributing to high adoption in the retail sector. Consumer trends such as high awareness, and demand for bio-based reusable materials is likely to be witnessed all across the mature markets. Overall, the reusable straw industry is poised to exhibit a high growth rate in the next three years.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=11464&license_type=Single%20User

Indoor fitness trends such as calorie burnout, cardio, open air gymnasium and power yoga are gaining high momentum and therefore the market for home fitness equipment is anticipated to value at USD 15bn in the next three years. Most commonly used equipment are treadmills, stationary bikes and elliptical are in high demand across the global markets. Moreover, the need for maintaining high fitness levels to combat lifestyle diseases is widely witnessed in the urban settings. Professional commitments and time constraints have been fueling the concept of home fitness equipment in the metropolitan cities. Ranging from small to large, fitness equipment for indoors enjoy a wide popularity in urban scenarios.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=2204&license_type=Single%20User

The digitalization for broadcast and entertainment sector is expanding and the proliferation of digital channels via internet is most evident. As a result, there is a huge consumer demand for OTT content. Although, the OTT service market is relatively at nascent stages, the market is projected to reach at USD 33bn in the next five years. Dominance of smartphone technology and increased adoption of large screen smartphone is a driving factor across developed nations. Moreover, emergence of hardware compatible devices that support OTT content is resulting in a wide popularity. In addition, developments in the telecommunications sector for video calling and messaging service induces the market position for OTT platforms.

Buy complete research report on surgical robot: https://www.upmarketresearch.com/reports/over-the-top-ott-services-market

Food and beverages remains a hot domain for companies to invest in 2020 as confectionery processing equipment segment is expected to show optimal growth valued at USD 5bn in the next three years. There has been a huge popularity of chewing gums, jellies and bakery products in the retail industry. In addition, strong presence of retail companies stimulates the market growth for confectionery processing equipment. Stringent guidelines from USFDA and FAO are shaping up the industrial structure for processing equipment and continue to dominate the business policies. The North American market is a fast-paced market attributing to strong presence of major vendors and players.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=77570&license_type=Single%20User

The global market size of plastic to fuel technology was USD 82mn in 2018 and it is expected to reach at USD 2.50bn in the next five years according to a research report. Major trends such as government policies to influence plastic to oil conversion and developing distribution channels is gaining tremendous traction. Growing awareness for plastic consumption and improved disposal methods are major highlights. Moreover, it is also estimated that the plastic to fuel technology market offers lucrative employment opportunities. For instance, in the U.S. plastic based fuel is gaining a high momentum due to low content of sulfur.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=82610&license_type=Single%20User

The market size for recycled plastics is expected to bypass USD 67bn in the next five years attributing to the Y-o-Y (year on year) growth across the global market. Polyethylene Terepthalate is a widely used recycled material. Commercially, PET offers lucrative growth opportunities and exhibits high reusable capacity. High density polyethylene holds a maximum share in the global market and expected to grow at a stipulated CAGR. For instance, high density polyethylene is usually employed for margarine tubes, grocery bags, and cleansing bottles. Recycled plastics seem to have a high influence in the consumer appliance industry, therein the market for recycled products witness a strong demand.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=82613&license_type=Single%20User

The worldwide construction and real estate business is undergoing rapid innovations, norms and standardized regulations. Demand for quality home is witnessed all across the economies thereby enabling the market to come up with modernized approach in the construction phase. The construction additives is a growing market particularly in the developing economies as the global market is expected to reach at USD 23bn in the near future. Economic reforms and revival post economic crisis in 2008 is much likely to create a balanced market ensuring a high-end growth. In addition, the widening landscape of urbanization within the Asia Pacific market stimulates the ongoing developments.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=8024&license_type=Single%20User

The global market share for automotive and vehicle equipment is expected to cross USD 300bn in the next 5-10 years as the year 2020 is the most automotive year. Alarming need for enhanced safety in vehicles and smooth ride are some of the basic factors that demand a vehicle complying to international safety standards. Suspension is a pivotal component in an automotive that is subsequent in enabling a smooth and shock free ride. It also prevents any wear and tear of cargo and protects the passengers from drifting. Use of pneumatic and hydraulic suspension types are some of the modern methods used in designing suspension for a vehicle, says a market report. Increase in rate of inter-state IMEX business with road transport being the crucial mode of transportation propels the demand for heavy commercial vehicles. There have been drastic rise recorded in the past few years which is anticipated to keep rising annually at a higher rate.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=129774&license_type=Single%20User

Liquid waste management is a prime concern in the developing economies since marine pollution is relatively high. Therefore, strong initiatives led by NGOs and helping communities have resulted in developing a sustainable system for managing liquid waste and hence the commercial market is gaining a lot of traction. It is also anticipated that the market might gain 4.0% CAGR in the next couple of years thanks to awareness and change in trends for disposal of liquid waste. Industrial liquid waste is associated with potential toxicity posing a serious threat to marine life, on a large scale. Accumulation of hazardous effluents is expected to drive the demand for liquid waste management initiatives in the near future. Apart, stringent norms and government regulations for commercial industries is expected to drive the market development in the forthcoming years.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=129787&license_type=Single%20User

Semi-agriculture is relatively a growing domain wherein innovation in farming are been tried and tested. According to a research study, the global market share for humic acid water soluble fertilizers is poised to bypass USD 130bn in the near future. Notable growth factors such as enormous demands for organic fertilizers over synthetic ones driven by high preference is most evident. Advantages offered are humic acid fertilizers boosts disease resistance in plants, acts as a color enhancement and moreover ensures high nutrition in plant growth. Europe is a fast-paced growing market and reveals ideal growth trends in the international market.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=77329&license_type=Single%20User

As mentioned above, 2020 being the most automotive year as there will be a lot of happenings in automotive industry ranging from launch of automatic vehicles to discussion panel for flying cars. Although, the holistic market seems to be optimal in terms of revenue, the braking units category is the most remarkable. In addition, braking systems in automatic vehicles are quite sophisticated and offer more accuracy. The trend of hydraulic braking systems is gaining much attention in the past years and is expected to reveal lasting effects on the global market. Adherence of international safety standards and certifications have a crucial role in the development of automotive disc brake market.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=108703&license_type=Single%20User

According to a research study, the aerospace industry creates more jobs than any other sector. In this regards, aerospace coatings domain is a fast and emerging sector wherein it is valued at USD 2.3bn by end of 2022. Demand for technical competence, knowledge of signs and symbols in the aerospace industry and high adoption of nanotechnology in the MRO for aerospace. In addition, growing significance of nano-structure metals with low carbon footprint is expected to have a huge impact on the global market. Apart, revision of policies in the aviation industry in Asia Pacific market is expected to impart growth opportunities in the coming years.

Buy complete research report on surgical robot: https://dataintelo.com/checkout/?reportId=11504&license_type=Single%20User

Market research trends in 2020 will be more data-driven and companies are willing to spend more. The deciding factor is what data they are looking and the level of input to start with, and this is possible having an insight partner around the corner. So, do let us know what you think and by leaving a comment.

Go here to read the rest:
20 Markets to lookout for in 2020 - Expedition 99

Read More...

Douglas Rosenthal on Strengthening the Immune System – Patch.com

January 30th, 2020 3:42 pm

Strengthening the immunity is a very important thing. In order to be in top shape, healthy, strong, cheerful, energetic and maximally productive, we must take care of our mind and body. For our organism to work as a perfect mechanism, we must keep an eye on its parts and take care of every beat. For the perfect pulse, a resistant and healthy organism, it is necessary to provide the body with strong immunity.

The function of the immune system is to protect the body from all factors that could impair our health. With a severely damaged immune system, no one can survive despite the treatment with the most effective antibiotics. On this occasion, research scientist and structural biologist Douglas Rosenthal shares some helpful ways to strengthen your immune system and fight off disease.

Doug Rosenthal conducts research studies of the molecules that form cells and pathogens. He focuses on how pathogens infect and cause disease by producing virulence factors that target host cell molecules.

Immune system function. Why is it so important?

The immune system is activated every time a foreign body or organism is found in the human body. These are usually microorganisms (bacteria, viruses, fungi) as well as pollution particles or toxins, and we call these factors antigens. There are millions of antigens that can even have slight differences between them, which are recognized by the immune system and triggered by a response called the immune response. It is a very important task of this system to remember foreign matter and distinguish it from those belonging to the human body.

Immunity is the ability of an organism to defend itself by its mechanisms against viruses, infections, bacteria, parasites and other pathogens. As biologist Douglas Rosenthal says, there are several types of immunity, naturally acquired, artificially acquired, active and passive.

Naturally acquired immunity is one that the baby inherits from the mother, that is, antibodies that, during pregnancy, the mother transmits via the placenta to the fetus or via milk to the infant.

Artificially acquired immunity is an artificially enhanced organism to fight disease, that is, to inject antibodies that are introduced into the body, for example through vaccination.

Active immunity is created and renewed throughout life. For example, when a virus invades the body, the body creates cells that remember the body's defense response to that virus, and the next time the same virus attacks the body, the body already knows how to defend itself (healing diseases).

Passive immunity is an antibody transfer but it is not long lasting. Artificially made immunity is resorted to when there is a high risk that, for example, a particular virus will invade an organism, and there is not enough time for the organism to generate antibodies for defense itself.

How to strengthen your immunity in the best way

Above all, one should pay attention to lifestyle. Enough sleep - at least eight hours, regular physical but well-chosen activity, preferably three times a week, staying in nature, relaxing with loved ones, eliminating stress, enough water intake, recommended dose at least 8 glasses a day.

Listening to and taking care of your body is certainly a real weapon against the wicked enemies that lurk every moment of weakness to attack our bodies.

Being in harmony with immunity

According to researcher Douglas Rosenthal, the individual part must always be connected to the whole, if the whole is not right, its parts will suffer. To cure the disease is primarily to enable the body as a whole, or ideally, to function in accordance with its environment. In order to get the best recipes and guidelines, instructions and recommendations, it is necessary to monitor your body's signals and consult with a professional for further steps.

See the article here:
Douglas Rosenthal on Strengthening the Immune System - Patch.com

Read More...

Food to Boost Your Immune System and Fight the Flu – The National Herald

January 30th, 2020 3:42 pm

By Eleni Sakellis January 24, 2020

Spinach salad. Photo: By cyclonebill, via Wikimedia Commons

Foods that boost your immune system can help keep you healthy all year long, even in the midst of cold and flu season. Simple, nutrient-rich foods, full of anti-oxidants that fight free radicals support immune health. The gut is also a major part of the bodys immune system and keeping the gut healthy contributes to our overall health and well-being. A balanced diet and moderate exercise are not only good for you, they help you feel better as well, even if the long, dark winter is getting you down. Try the following recipes to help keep your immune system in top condition. For those who unfortunately do come down with cold or flu symptoms, consult your physician.

Healthy Smoothie

1 cup fresh baby spinach3/4 cup frozen green grapes1/2 cup brewed green tea, cooled1 medium ripe kiwi, peeled and chopped1 sprig fresh mint leaves1/2 medium apple, cored and chopped

Add the spinach, grapes, green tea, kiwi, mint, and chopped apple to the bowl of a blender. Blend until smooth, adding water if needed for the desired consistency.

Spinach and Feta Salad with Walnuts

1/3 cup walnuts, chopped1 lemon1/4 cup Greek extra virgin olive oil1 package fresh, pre-washed baby spinach1 Granny Smith apple, thinly sliced1/2 cup crumbled fetaGreek sea salt and freshly ground pepper to taste

Toast the walnuts in a dry pan over medium heat, stirring for about two minutes until their fragrance is released, careful not to burn them. Transfer to a plate to cool slightly. In a mixing bowl, whisk together the juice of half the lemon and the olive oil. Add the spinach, apple slices, walnuts, salt and pepper to taste and toss to coat with lemon and olive oil. Add additional lemon juice to taste, if preferred. Serve immediately.

Healthy Fruit Salad

Apples, choppedOranges, peeled and sectionedKiwis, peeled and dicedPineapple, choppedGrapesPomegranate seeds2 tablespoons finely chopped fresh mint, optionalGreek yogurt, optional

Place the cut fruits in a large bowl and mix carefully to combine. Add the grapes, cutting in half if they happen to be very large, stir and garnish the top with pomegranate seeds and fresh mint, if using. For adults only, add half or a whole bottle of white wine or champagne for special occasions, and stir. Let the fruit salad marinade for half an hour or refrigerate for up to 2 hours. Stir before serving in individual bowls, spooning some of the liquid over the top. Any leftover juices and wine make for a refreshing drink. For more Greek flavor, serve with Greek yogurt for extra protein. If preferred, top with your favorite flavor of ice cream and enjoy as a sundae.A diversity of fruits in your fruit salad adds complexity and interest, not to mention vital phytonutrients to your diet. Use about a cup of fruit per person to determine the amount of fruit you will need for your salad. The fruits listed in the recipe are suggestions, so choose your favorites and enjoy.

Here is the original post:
Food to Boost Your Immune System and Fight the Flu - The National Herald

Read More...

‘Make sure immune system is strong and fit to fight’ – New Straits Times

January 30th, 2020 3:42 pm

KUALA LUMPUR: As international scientists and medical experts strive to find a cure and vaccine for the 2019 novel coronavirus (2019-nCov), there is also a need for Malaysians to play their part by strengthening their immune system.

Boosting the immune system would help the body fight viruses and bacterial attacks, said Malaysian Medical Association president Dr N. Ganabaskaran.

He said Malaysians should practise good eating habits and choose food that strengthened the immune system.

He said a strong immune system could reduce the risks of viral and bacteria infections.

The immune system can help the body fight infections caused by viruses and speed up the recovery process after an infection.

The immune system is the bodys defence against infectious organisms and other invaders.

The immune system is made up of a network of cells, tissues and organs that work together to protect the body.

However, Dr Ganabaskaran, said everyones immune system was different due to factors such as age, eating habits and lifestyle.

Thus, it is important to make sure that our immune system is strong and fit to fight.

One of the most important vitamins that boosts the immune system is Vitamin C.

Malaysian Medical Association president Dr N. Ganabaskaran. - NSTP/ASYRAF HAMZAH

A lack of Vitamin C can make you more prone to getting sick.

Then we have Vitamin B6, which is vital in supporting biochemical reactions in the immune system, and thirdly, Vitamin E, a powerful antioxidant that aids the body to fight off infections.

He stressed the importance of getting enough vitamins for a stronger immune system.

He said a healthy diet and adequate consumption of vitamins were essential for a strong immune system.

Consuming food that boost the immune system was encouraged in light of the influenza and 2019 n-CoV outbreak, he said.

He said food that boost the immune system included green vegetables, dairy products, kiwi fruit, lemons and oranges, as well as nuts like almonds and cashew, which were high in vitamins and antioxidants.

Even cooked poultry and shellfish are important immune boosters due to the protein and zinc they provide. It is also advisable to avoid consuming half-cooked or raw food for a while.

Shellfish that are high in zinc include crab, clams, lobster and mussels. However, observe the daily recommended amount (11mg for men and 8mg for women). Too much zinc can inhibit the immune system. Deficiencies in Vitamin D may lead to poor bone growth, cardiovascular problems and a weak immune system.

Choose supplements that contain D3 (cholecalciferol), since its good for raising your blood levels of Vitamin D.

Nutritionist Dr Sareena Hanim Hamzah said a balanced diet comprising carbohydrates, protein, fat, vitamins and minerals, as well drinking enough water, were essential to boosting the immune system.

Fruits and vegetables of various colours are important for the body to replenish and strengthen ones immunity. Fruits and vegetables contain Vitamin C, E and antioxidants that can enhance the immune system to fight against infections and pathogens.

She said citrus fruits and berries were among the best for strengthening the immune system. For vegetables, she recommended bell peppers, broccoli and spinach.

However, consumption must be in moderation.

Generally, people without any underlying health issues will not be affected by slightly higher intake, but for people who may have pre-existing health conditions or have had medical procedures done, for example to the heart, its best to consult a nutritionist for a customised regime.

Sareena said besides fruits and vegetables with high Vitamin E, a powerful antioxidant, seeds were also essential for boosting the immune system.

For instance, she said, sunflower seeds had phosphorous, magnesium and Vitamin B6.

Vitamin E is important for regulating and maintaining immune system function. Other foods with high Vitamin E include avocados, dark leafy greens and nuts.

Based on scientific research from around the world, garlic, ginger, dark chocolate and green tea are also good for the body, she said, adding that Vitamin D and probiotics from yogurt improved the immune system.

Vitamins B6 from poultry and foods with Vitamin D were recommended, she said.

Sareena urged people to practise good eating habits and stay away from processed food.

Same thing applies to high-sugar food and drinks as they may act just the opposite and accumulate unnecessary fats or lead to other medical problems.

To stay fit and have a strong immune system, people should complement a good diet with frequent or regular exercise for the best results.

Go here to read the rest:
'Make sure immune system is strong and fit to fight' - New Straits Times

Read More...

Jounce Should Be On Your Radar With Differentiated Approach To Activating Immune System – Seeking Alpha

January 30th, 2020 3:42 pm

Jounce Therapeutics (NASDAQ:JNCE) is a biotech that should be on your radar in the coming weeks. That's because it is set to present new data from the ICONIC trial for its vopratelimab drug to treat patients with advanced solid tumors. This presentation will pretty much show why an RNA signature was selected to become a predictive biomarker for the potential of improved clinical outcomes in cancer patients. With such data on hand, there is an ability to initiate the phase 2 SELECT study in 2020 to use vopratelimab in combination with its other PD-1 inhibitor product known as JTX-4014. Besides this mid-stage SELECT study, there is another trial ongoing known as EMERGE. Both of these studies provide shots on goal for the monoclonal antibody of vopratelimab. A few catalysts in 2020 could help boost the value of the stock.

Why I believe that Jounce Therapeutics is a good speculative biotech is because of its approach to using a predictive RNA signature biomarker to potentially help increase clinical response rates in patients with certain types of cancer. I am taking the stance that future immunotherapy products are leaning more towards biomarker targeted drugs. That's why Jounce intends to initiate a phase 2 study with vopratelimab in mid-2020 known as SELECT. The basis of this study is that a predictive RNA signature biomarker will help choose only those patients who are to likely respond to treatment. I'm not bullish on this speculative biotech only because of the predictive biomarker approach being deployed in this study. It is also because along with the use of vopratelimab, Jounce intends to add into the mix its mid-stage ready PD-1 inhibitor asset known as JTX-4014. The data to be presented at the ASCO-SITC 2020 conference, taking place between February 6th through the 8th, will display the biomarker RNA signature of ICOS hi CD4 T-cells to be described below. Specifically, from the ICONIC study. What's the rational reason for deploying such a study? That's because in a prior phase 1 study, known as ICONIC, it was shown that patients were able to show a benefit against multiple measures when using vopratelimab alone or in combination with another PD-1 inhibitor known as Opdivo (nivolumab). Such positive measures observed were:

The main mechanism of action for vopratelimab (monoclonal antibody) is that it binds to T-cells and activates "Inducible T-cell Co-Stimulator", thus the name ICOS. ICOS is a protein that is found on the surface of certain T-cells. What's important to note, which is shown above, is that ICOS only activates what is known as ICOS hi CD4 T-cells. These ICOS hi CD4 T-cells are the predictive biomarker to be deployed for the SELECT study. This brings up another point in that vopratelimab only engages CD4 T-cells and not CD8 T-cells. Why is that important? That's because CD4 T-cells are known to elicit a more robust response, while CD8 T-cells are not as keen. One other fact is that CD4 T-cells are known as helper cells, and they stimulate other immune cells in the body. They offer an adaptive immune response in both helping suppress and/or regulate immune responses. The initiation of the phase 2 SELECT study will be an important milestone for Jounce, which I believe will be a catalyst for the stock. The presentation of biomarker data at the ASCO-SITC 2020 conference will act as another catalyst. The mid-stage SELECT study will be initiated in mid-2020. From there, interim results from this study won't be released until 2021.

There is another shot on goal with the use of vopratelimab. This is a phase 2 study known as EMERGENCE, which had already been initiated in June of 2019. What's different about the EMERGENCE study is that it doesn't include a biomarker like the phase 2 SELECT study noted above. In other words, this is more of a broad approach to treating patients with cancer. Having said that, it doesn't get away from the main mechanism of action of vopratelimab, which is inducing ICOS hi CD4 T-cells to kill cancer cells. This phase 2 EMERGENCE study is going to be using the combination of vopratelimab + Yervoy (ipilimumab). Wait a second, why the need for Yervoy to be incorporated into this study? That's because Yervoy is an anti-CTLA4 inhibitor. It attaches to cancer cells and inhibits the CTLA4 response, which in essence helps boost the immune response against target cancer cells. There is another item that Yervoy does which is crucial and lines up with the mechanism of action of vopratelimab. It also induces ICOS hi T-cells like vopratelimab. Thus, the two products together each have a goal in this study:

So Yervoy acts like the launcher of inducing ICOS hi, and then vopratelimab is responsible for increasing such activity and then letting it sustain for a longer period of time. I believe such a mechanism has the chance to exhibit a more sustained durable response for cancer patients. This phase 2 study is being tested in patients with non-small cell lung cancer (NSCLC) and urothelial cancer. It is expected that efficacy and biomarker data from the EMERGE study will be revealed by the 2nd half of 2020.

According to the 10-Q SEC Filing, Jounce Therapeutics had cash, cash equivalents and investments of $185.1 million as of September 30, 2019. The company believes that it will have a gross cash burn between $80 million and $95 million for 2020. The company believes it has enough cash on hand to fund its operations into the second half of 2021. In my opinion, this is just an estimate. I think that once it initiates the phase 2 SELECT study, along with possibly advancing other early-stage studies, it is possible that the gross cash burn rate could increase. Another possible scenario is that it may choose to raise cash after positive data is released. When a company's stock trades higher on the back of positive clinical data, biotechs tend to take advantage with an immediate cash raise.

While some good preliminary data came from the phase 1 ICONIC study using vopratelimab in solid tumors was achieved, it is important to note that it is still in early-stage studies. There is no guarantee that the biomarker data to be presented at the ASCO-SITC 2020 conference is going to be highly positive. If that's the case, then it could be a non-event type of a catalyst. The other phase 2 studies noted above, EMERGE and SELECT still have a way to go before data is released for either of those. As for the EMERGE study, clinical data is not expected until the second half of 2020. The SELECT study has yet to be initiated and is not expected to begin until mid-2020. This means that in the short-term, it's quite possible that the stock could trade lower until such data is revealed.

Jounce Therapeutics is looking to take a differentiated approach with the use of its monoclonal antibody vopratelimab. As I laid out above, both phase 2 studies shown above will have one thing in common. That is the mechanism of action of vopratelimab in being able to induce ICOS hi T-cell responses to improved multiple measures in patients with cancer. One approach is to use Yervoy in combination with vopratelimab to accomplish this task. The other approach in the SELECT study is the use of a biomarker (ICOS hi T-cell population to benefit from treatment) and the addition of Jounce's very own PD-1 inhibitor JTX-4014. I believe that Jounce Therapeutics has a good shot to increase clinical outcomes for several cancer patient populations. Thus, I view it as a good speculative buy.

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Originally posted here:
Jounce Should Be On Your Radar With Differentiated Approach To Activating Immune System - Seeking Alpha

Read More...

Immunotherapy called the future of cancer care, but not without risks, costs: Health Matters – cleveland.com

January 30th, 2020 3:42 pm

Q: What is immunotherapy, and what kinds of cancer can it treat?

A: Immunotherapy is a cancer treatment that activates a patients immune system to identify and destroy diseases such as cancer.

Immunotherapy is the future of cancer care, said Dr. Theodoros Teknos, president and scientific director of the University Hospitals Seidman Cancer Center and deputy director of the Case Comprehensive Cancer Center.

This type of treatment is being used to fight a number of cancers of the blood and solid organs such as the liver, spleen, kidneys, adrenals, pancreas, ovaries and uterus. It has been shown most effective in lymphomas, leukemias, melanoma and lung cancer, Teknos said.

The Cleveland Clinic annually treats a few dozen patients with immunotherapy vaccines, the health system said.

Some patients who undergo immunotherapy treatments see their cancerous tumors disappear, said Dr. Dale Shepard, medical oncologist at the Cleveland Clinics Taussig Cancer Center.

A 2019 clinical trial suggested that immunotherapy could give some men with advanced prostate cancer who have exhausted all other treatment options two years or more of life.

UH and the Cleveland Clinic are using these therapies to treat cancer and conducting clinical trials of new immunotherapies. MetroHealth System is holding clinical trials of a new form of immunotherapy for women with recurrent cervical cancer.

UH is the only Midwest site taking part in a new clinical trial investigating the use of immunotherapy on glioblastoma, a type of brain cancer. The trial uses a modified polio virus to target tumor cells and kill them directly, and create an anti-tumor immune response to kill additional tumors.

This is the hottest area of research, Teknos said.

A patients age has no bearing on how well immunotherapy will work, Shepard said. He gave the example of former President Jimmy Carter, who at age 95 is being treated with immunotherapy.

Immunotherapy holds great promise, but it has limitations. The treatments can be used for only some types of cancer, and can come with severe side effects. Costs also can spiral north of $100,000.

Here are some often-used types of immunotherapy:

Immune checkpoint inhibitors

Cancer cells secrete a protein that turns off the immune system. Checkpoint drugs allow the bodys immune system to identify cancer cells and fight them, Teknos said.

Checkpoint inhibitors take the tumors Invisibility Cloak off, UHs Teknos said, using a Harry Potter reference.

Checkpoint inhibitors currently on the market include the brands Keytruda (Pembrolizumab) and Opdivo (Nivolumab).

Checkpoint inhibitors hold the potential for very, very good and long-lasting responses, Shepard said. Chemotherapy typically will not do that.

CAR-T cell therapy

Bodies fight infection using a type of immune cell called T cells. CAR-T-cell therapy works by removing T-cells from a patients blood and modifying them in a laboratory to chimeric antigen receptors (CAR). These altered T-cells are returned to the patients body, where they recognize and destroy cancer cells.

They go out and seek tumors, Shepard said.

Cancer vaccines

Some types of anti-cancer vaccines target specific proteins found on cancer tumors. This type of anti-cancer vaccine has to be specially tailored for a specific patient.

FDA-approved vaccines include Provenge (sipuleucel-T), which is infused through an IV, for prostate cancer, the Clinic said. Another anti-cancer vaccine is talimogene laherparepvec (T-VEC) for melanoma; it is injected into the tumor.

Other anti-cancer vaccines utilize viruses that grow inside tumors and cause the cancerous cells to break apart. This allows the bodys immune system to recognize and destroy cancer cells.

There are serious risks

Immunotherapy isnt always successful. Some patients see their tumors shrink, but others see no response, or their tumor increases in size, Shepard said.

We dont know how to tell whos who, Shepard said.

Theres evidence that in some cases, ramped-up immune systems created by these therapies attack healthy organs, according to a 2016 New York Times article.

Studies suggest that severe reactions occur nearly 20% of the time with certain drugs, and in more than half of patients when some drugs are used in combination.

Patient deaths led Seattle-based Juno Theraputics to permanently shut down its clinical trial of an immunotherapy to treat acute lymphoblasic leukemia in adults, according to a 2017 Seattle Times article. Five patients in the trials died, but the fifth death could not be tied to the trial. Juno Theraputics did not respond to requests for comment.

Expensive care

Because immunotherapy treatments are time-consuming to make, and sometimes must be personalized for individual patients, they often cost more than $100,000 per patient.

When the therapies are used in combination, costs can double or triple, according to the online publication Vox. For example, CAR-T is $350,000 to $500,000 per treatment, Teknos said.

Private health insurance companies sometimes wont cover immunotherapy costs, even if a physician recommends the treatment, according to Vox. Copays are so high that they put the treatment out of reach for most people, the article said.

Medicare doesnt cover the costs of Keytruda or Optivo, according to GoodRx.

When immunotherapy is given to a hospital inpatient, it is included under the diagnosis-related group payment system used to determine hospital payments, a Medicare spokesman said. Local Medicare administrators determine Medicare coverage for outpatient immunotherapy treatments.

Further reading

More detail about Medicare coverage of immunotherapy

The Society for Immunotherapy of Cancer (SITC)

This professional society for the advancement of immunotherapy offers a 40-page booklet free to download.

Cancer.Net

Additional information on immunotherapy in each cancer-specific section.

GoodRx lists patient assistance programs for Opdivo.

ResearchMatch

This is an NIH-funded free registry for people trying to find research studies to join.

Recent Health Matters columns by Julie Washington:

Hospitals say leave meds at home; readers say otherwise

Where to get help paying your medical bill

Tips for a smooth transition to a skilled nursing facility

Local celebrities share their healthy 2020 resolutions: Health Matters

Creating healthy habits for 2020: Health Matters

Shingles vaccine and virus: What you need to know: Health Matters

In her column, patient advocacy writer Julie Washington will answer readers questions about navigating health-care systems. (She will not address individual treatments.) Your comments may be published in a future story or column. Send questions and comments for publication including your name, city and daytime phone number to jwashington@plaind.com. You can also find Julie on Twitter @JulieEWash.

View post:
Immunotherapy called the future of cancer care, but not without risks, costs: Health Matters - cleveland.com

Read More...

Will There Be a Vaccine For The New Wuhan Coronavirus? If So, When? – ScienceAlert

January 30th, 2020 3:42 pm

Work has begun at multiple organizations, including the National Institutes of Health, to develop a vaccine for this new strain of coronavirus, known among scientists as 2019-nCoV.

Scientists are just getting started working, but their vaccine development strategy will benefit both from work that has been done on closely related viruses, such as SARS and MERS, as well as advances that have been made in vaccine technologies, such as nucleic acid vaccines, which are DNA- and RNA-based vaccines that produce the vaccine antigen in your own body.

No, but work was ongoing for other closely related coronaviruses that have caused severe disease in humans, namely MERS and SARS.

Scientists had not been concerned about this particular strain, as we did not know that it existed and could cause disease in humans until it started causing this outbreak.

Work on vaccines for severe coronaviruses has historically begun once the viruses start infecting humans.

Given that this is the third major outbreak of a new coronavirus that we have had in the past two decades and also given the severity of disease caused by these viruses, we should consider investing in the development of a vaccine that would be broadly protective against these viruses.

This work involves designing the vaccine constructs for example, producing the right target antigens, viral proteins that are targeted by the immune system, followed by testing in animal models to show that they are protective and safe.

Once safety and efficacy are established, vaccines can advance into clinical trials in humans. If the vaccines induce the expected immune response and protection and are found safe, they can be mass produced for vaccination of the population.

Currently, we lack virus isolates or samples of the virus to test the vaccines against. We also lack antibodies to make sure the vaccine is in good shape. We need the virus in order to test if the immune response induced by the vaccine works.

Also, we need to establish what animals to test the vaccine on. That potentially could include mice and nonhuman primates.

Vaccine development will likely take months.

We expect that these types of outbreaks will occur for the foreseeable future in irregular intervals.

To try to prevent large outbreaks and pandemics, we need to improve surveillance in both humans and animals worldwide as well as invest in risk assessment, allowing scientists to evaluate the potential threat to human health from the virus, for detected viruses.

We believe that global action is needed to invest in novel vaccine approaches that can be employed quickly whenever a new virus like the current coronavirus and also viruses similar to Zika, Ebola or influenza emerges.

Currently, responses to emerging pathogens are mostly reactive, meaning they start after the outbreak happens. We need a more proactive approach supported by continuous funding.

Aubree Gordon, Professor of Public Health, University of Michigan and Florian Krammer, Professor of Vaccinology, Icahn School of Medicine at Mount Sinai.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Link:
Will There Be a Vaccine For The New Wuhan Coronavirus? If So, When? - ScienceAlert

Read More...

Engineered symbionts activate honey bee immunity and limit pathogens – Science Magazine

January 30th, 2020 3:42 pm

Inducing immune bee genes

Honey bees are prone to parasitism by the Varroa mite, which is a vector for several bee pathogens. However, honey bees are also host to the symbiotic gut bacterium Snodgrasella alvi. Leonard et al. engineered S. alvi to produce double-stranded RNA (dsRNA)a stimulus for insect RNA interference defense responsesfrom a plasmid containing two inverted promoters tagged with a fluorescent label (see the Perspective by Paxton). This dsRNA module can be targeted to interfere with specific bee genes as well as crucial viral and mite genes. The authors found that gene expression could be blocked for at least 15 days as the symbionts established in the bees' guts and continuously expressed the dsRNA constructs. S. alvi with specifically targeted plasmids not only suppressed infection with deformed wing virus but also effectively reduced Varroa mite survival.

Science, this issue p. 573; see also p. 504

Honey bees are essential pollinators threatened by colony losses linked to the spread of parasites and pathogens. Here, we report a new approach for manipulating bee gene expression and protecting bee health. We engineered a symbiotic bee gut bacterium, Snodgrassella alvi, to induce eukaryotic RNA interference (RNAi) immune responses. We show that engineered S. alvi can stably recolonize bees and produce double-stranded RNA to activate RNAi and repress host gene expression, thereby altering bee physiology, behavior, and growth. We used this approach to improve bee survival after a viral challenge, and we show that engineered S. alvi can kill parasitic Varroa mites by triggering the mite RNAi response. This symbiont-mediated RNAi approach is a tool for studying bee functional genomics and potentially for safeguarding bee health.

Originally posted here:
Engineered symbionts activate honey bee immunity and limit pathogens - Science Magazine

Read More...

Water therapy, adequate sleep: Ways to boost immune system to avoid 2019nCoV – ABS-CBN News

January 30th, 2020 3:42 pm

MANILA - A strong immune system and avoiding interaction with those infected with the new coronavirus are the best ways to block the illness, a public health expert said Tuesday.

The mysterious new strain, which can cause a pneumonia-like acute respiratory infection, has so far killed 106 people in China and infected some 4,000 across the world.

"The only thing that will help us fight off the disease is not interact with those who are sick," Dr. Susan Mercado told ANC's Headstart.

"Have a balanced diet, sleep the right number of hours, get good physical exercise. Its about staying healthy, eating fruits and vegetables, drinking a lot of water."

The new virus could be spreading through droplets, for instance when people sneeze or cough, or through direct contact with infected people or with objects they have touched, the World Health Organization said.

It remains unclear if the virus, known as 2019nCoV, is contagious before symptoms of fever or respiratory difficulties appear, it added.

"This virus is in human beings. What we need to do is limit the movement of those who are sick and avoid those who are sick. If they get well and they fight off the virus, the virus dies in them," Mercado said.

The Philippines has yet to confirm a case of the mysterious new strain of virus but it will be able to conduct tests for the virus "within the week," according to Mercado.

Manila earlier sent to Australia the specimen of a child in Cebu who came from Wuhan and tested positive for non-specific coronavirus. The child's specimen later yielded a negative result for the 2019nCoV.

Eleven foreigners in the Philippines are quarantined for possible infection from the Wuhan coronavirus, the health department said Monday.

View original post here:
Water therapy, adequate sleep: Ways to boost immune system to avoid 2019nCoV - ABS-CBN News

Read More...

Mechanism of Natural Cancer Regression Revealed Through Theory Behind AllerPops – Yahoo Finance

January 30th, 2020 3:42 pm

LOS ALAMOS, N.M., Jan. 28, 2020 /PRNewswire/ --Knoze Jr Corp releases the study that led to the development of AllerPops, a prebiotic lollipop that gives people lasting allergy relief. The theory proposed in the article explains not only why we have allergies but also how the immune system starts to fight cancer after an infection, which leads to the rare natural cancer regressions. This understanding makes it possible to develop a novel immune therapy that is inexpensive and without dangerous side effects.

When cancer goes away on its own, it's so rare that people often say it's a miracle.

Peregrine Laziosi (12601345) is the patron saint of cancer patients. When he was in his sixties, he developed bone cancer and his only option was to have his leg amputated. The cancer swelled his bone so much that it broke through the skin and it became infected and gave a stinky smell. Miraculously, by the time of his scheduled operation, the doctor found his cancer completely disappeared. Saint Peregrine lived another 20 years before he died at age of eighty-five years old.1

A more recent miracle was used as evidence for the canonization of St. Elizabeth Ann Seton (1774-1821) in 1975. In 1952, Anne Theresa, who was 4, was dying of leukemia. A relic, a cloth touched to Mother Seton's remains, was pinned to the child's gown. Anne almost immediately recovered, and her leukemia was completely healed. 2

The record also shows that just before her recovery, Anne Theresa had severe chickenpox with high fever and nutritionally, she could only tolerate sips ofCoca-Cola. 2

Is there a medical explanation for these miracles?

Cliff Han is the founder of Knoze Jr Corp, a startup firm located in Los Alamos, NM, and inventor of AllerPops. When he reviewed the cases of these cancer miracles, he wanted to find a medical explanation for these acts of God.

"In the two miracles, the people who experienced a natural cancer regression had a serious infection right before the miracle occurred," said Han. "Other than the fact that their immune systems were stimulated by the infections, we still do not know the mechanism leading to the cancer regression."

His study that led to the development of AllerPops, may shed some light on the matter.

AllerPops are prebiotic lollipops that give people lasting allergy relief by targeting the root cause of allergies, a lack of friendly bacteria in the oral cavity.

But what do allergies have to do with cancer?

Han's Theory of Negative Trigger (TNT), developed to explain why we have allergies, can also elucidate how an infection initiate the immune system to fight for cancer.

"If we know how these cancers went away miraculously, we can lead the way for these types of miracles to happen to more people more often," said Han.

TNT describes the relationship between our microbiota and immune systems. Briefly, our immune system is like a car with an accelerator to speed it up and brakes to slow it down. Pathogens acts as an accelerator, stimulating the immune system so it can protect us from infectious diseases. Probiotics (friendly bacteria) act as brakes, slowing it down when there is no infection. Like the car, our immune system is designed to be parked most of the time by the brakes our probiotics.

Our immune system operates in the gut (70%), airway (25%) and under our skin. Different probiotics live in these biological niches and send signals to pacify our immune system. These interactions are primarily local and limited by space and time. The peace agreement between probiotics and the immune system makes it possible for us to live peacefully in the environment.

Read the article that explains TNT here, https://allerpops.com/oral-probiotic-deficiency-may-cause-common-allergies/

How can you stimulate the immune system so it's ready to fight off cancer?

According to Han, a biologist worked at Los Alamos National Laboratory (LANL) for 22 years, two things must happen so that our immune system can be ready to go into battle with cancer.

Both conditions can be automatically fulfilled when a natural infection takes place. A high fever will remove the probiotics that live in the mouth and airway. Diarrhea will remove probiotics in the gut. Reduced appetites will also starve the probiotics in the gut. Pathogens and the damage they cause stimulate the immune system.

Story continues

For example, in the miracle of Anne Theresa described above, the chickenpox infection stimulated Anne's immune system. She had a high fever which inhibited the growth of probiotics in the airway. Drinking only Coca-Cola provided no fiber (food) to the gut probiotics. Without those probiotics, her immune system mobilized at a high level so it could fight the chickenpox virus and the leukemia cells without reservation.

Cancer miracles may happen more frequently if we do these things intentionally. Stimulating the immune system and removing brakes (the friendly bacteria) are both necessary to kick-start the immune system.

How to remove probiotics from your system

Probiotics need food to survive, and so you can slow down their growth by not giving them food. Han said, "I personally did a liquid-only fast (two cups cranberry juice, about 200 calories each day) for a week together with intensified oral hygiene."

How do you activate the immune system?

Recent studies of germ-free mice tested in a sterilized environment where there are no pathogens or probiotics3 indirectly show that removal of probiotics by itself will not activate the immune system.

Some cancer may stimulate the immune system, while most do not.

Therefore, in most cases, one will need vaccines or pathogens to stimulate the immune system. Currently, it is not known how strong the stimulation should be. Stimulation from common cold virus might be too weak. Can controlled chickenpox infection be applied? Only future study will tell.

A bio-firm is developing cancer treatment with Dengue virus stimulating an immune response.4 It is not certain if they included any procedure to remove the brakes.

Instead of using real pathogens/vaccines, controlled infusion of a proper combination of cytokines may be another way to stimulate the immune system.5

The stimulation of the immune system should be done the same time as removing the probiotics in both the airway and gut. Repetitive stimulation may be needed. This method can work alone or be used to improve the performance of modern immune therapy such as PD-1 blocker.

In addition to the explanation of the cancer miracle, the TNT theory suggests other beneficial health practices as well, such as how to prevent allergies, how to recover from a cold faster and why you should keep a fever.

Please check related blogs at allerpops.com/blogs/.

Contact:Cliff HanFounder of AllerPops and owner of Knoze Jr505-695-4236 233085@email4pr.comhttps://www.allerpops.com

References:

View original content to download multimedia:http://www.prnewswire.com/news-releases/mechanism-of-natural-cancer-regression-revealed-through-theory-behind-allerpops-300994081.html

SOURCE Knoze Jr Corp

The rest is here:
Mechanism of Natural Cancer Regression Revealed Through Theory Behind AllerPops - Yahoo Finance

Read More...

Connecticut Sees Spike In Number Of Flu Cases – Daily Voice

January 30th, 2020 3:42 pm

Cases of the flu spiked statewide in Connecticut, with more than 250 people hospitalized and three more deaths in the past week.

According to the Department of Health, the flu is currently widespread statewide, with a total of 1,036 influenza-related hospitalizations reported since the beginning of the flu season.

As of Saturday, Jan. 25, there has been a total of 23 deaths reported, all from residents over the age of 65. No pediatric deaths have been tied to the flu.

There were 4,684 positive influenza tests reported to the Department of Health, with the percentage of emergency department visits for influenza-like illness up 14.36 percent statewide, higher than at this time last year. Influenza-like illnesses were at 7.39 percent, up from 5.87 percent last week.

Nationally, there have been there has been no less than 9.7 million flu illnesses, 87,000 hospitalizations and 4,800 deaths from flu during the current flu season, and health officials said things are expected to get worse before they get better.

In 2018 and 2019, 3,506 people were hospitalized with influenza-associated illness in Connecticut and 88 people died.

According to health officials, "in Connecticut, the Department of Public Health uses multiple systems to monitor circulating influenza viruses. During the influenza season, weekly flu updates are posted from October of the current year, through May of the following year."

The CDC said that reported cases of the flu tend to increase in November before peaking between December and February. Flu season typically lasts through the middle of the spring.

The organization estimates that flu has resulted in between 9.2 million and 35.6 million illnesses each year in the United States and several deaths. Of those illnesses, an estimated 9 percent were hospitalized.

According to the CDC, the flu infects the respiratory tract. As the infection progresses, the bodys immune system responds to fight the virus.

"This results in inflammation that can trigger respiratory symptoms such as a cough and sore throat. The immune system response can also trigger fever and cause muscle or body aches.

"When infected persons cough, sneeze, or talk, they can spread influenza viruses in respiratory droplets to people who are nearby. People might also get flu by touching a contaminated surface or object that has flu virus on it and then touching their own mouth or nose.

Click here to sign up for Daily Voice's free daily emails and news alerts.

Visit link:
Connecticut Sees Spike In Number Of Flu Cases - Daily Voice

Read More...

Americas Coronavirus: Containing the Outbreak of Trumpism – Common Dreams

January 30th, 2020 3:42 pm

The epicenter of Chinas coronavirus outbreak is widely thought to be a wet market in Wuhan. At such markets, seafood, chicken, and other conventional foodstuffs are on sale alongside live animals. You can buy more than just dogs and cats there. Local epicures also shop for more exotic fare like foxes, badgers, civets, and snakes.

The coronavirus is a pathogen that jumps from animals to humans. The wet market is the perfect environment for the disease to incubate, mutate, and eventually infect the unwary.

Think of Washington, D.C. as Americas political wet market.

Donald Trump is Patient Zero for Americas "kings disease," which is the metonymic translation of coronavirus.

Washington is a place where ordinary politics takes place. But sometimes exotic species are introduced into the nations capital. And thats when a new disease can incubate and mutate and spread throughout the system.

Donald Trump is Patient Zero for Americas kings disease, which is the metonymic translation of coronavirus. His delusions of grandeur were always dangerously infectious, but they only became lethal when he took up residence in the White House.

As Trump came into contact with the ordinary Republican members of Congress, the disease leaped into the American body politic. Virtually the entire Republican Party began to treat the president not as the head of state or the head of the party but as a kingand thus above politics and not subject to the same congressional constraints as previous presidents.

Political scientists are frankly incapable of explaining the current impeachment saga in Washington. It takes an epidemiologist to figure out how a set of politicians, with a wide range of intellectual capabilities from grandmaster to moron, can all deny over and over again the clear evidence in front of their eyes that the president committed impeachable offenses.

Sure, they are marching in lockstep with the party leadership. But it really seems as if theyre suffering from a more serious infection when so many of them have refused to accept the admission of more evidence even as they insist that the existing evidence is insufficient.

Trumpism is not, of course, restricted to the political wet market of Washington, D.C. Plenty of Americans scattered across the country are willing to kneel down before the putative king.

Its unclear how to address this larger outbreak or even if its possible. After all, despite incontrovertible evidence to the contrary, two-thirds of Trump supporters back in 2016 still believed Obama to be a Muslim. Theyve since added more Trump-inspired conspiracy theories to the list, such as Ukraines supposed involvement in hacking the 2016 presidential election. As with mad cow disease, there simply might not be a cure for this political dementia.

But the continuing outbreak of Trumpism goes beyond the headlines about Republican derangement syndrome in Washington or the fever dreams of the presidents so-called base. An equally concerning problem is how Trumpism has infected the entire American system. This is where the political coronavirus actually threatens lives.

Indeed, this systemic infection has put American democracy on life support.

But This Is Evil

Omar Ameen risked his life to bring his family to America. He didnt have a choice.

Born in Iraq, Ameen worried that he and his whole family would be killed by someone taking revenge for the crimes of his cousin, who belonged to al-Qaeda. He left for Turkey in 2012 and, after an exhaustive set of interviews with U.S. screeners, made it into the United States in 2014.

For four years, as Ben Taub relates in a fascinating story in The New Yorker, Ameen worked hard in America to provide for his family. In July 2018, however, U.S. authorities arrested him on the grounds that he had acted on behalf of the Islamic State by killing a police officer in Iraq. The Trump administration had determined that Ameen was a terrorist, one of those bad skittles that Donald Trump Jr. once tweeted about. A network of federal agencies worked overtime to compile an airtight case against Ameen.

The only problem was: Ameen was not in Iraq when the guard was killed. And he could prove it.

This proof, however, didnt seem to matter. The government pursued its case against Ameen regardless, arguing that any evidence gathered after Ameens arrest was only admissible in an Iraqi court, which meant that Ameen would have to be deported. In Iraq, meanwhile, a fair trial is unlikely. Suspected terrorists are routinely tortured into making confessions and then either executed or detained indefinitely.

Its bad enough when Donald Trump lies about, for instance, the big terrorist threat coming from refugees when, in fact, there are virtually no refugee terrorists (aside from several anti-Castro Cubans who arrived before 1980).

Its even worse when the entire federal government is restructured around this lie, when the federal agencies perpetuate this lie on a daily basis, and when innocent people like Omar Ameen get caught up in the web of these lies.

Ameens lawyer, Ben Galloway has been losing sleep over the case.

Its not the stress of going into the hearingits the trauma of coming out of it, the trauma of realizing what theyre doing. Its unconscionable. Seeing the level of infection, this willingness to go along, it makes me realize that we are not safe I hope we can recover from it. I hope we can regain institutional integrity in some of these agencies. None of them is perfectthey all have problematic historiesbut this is evil.

SCROLL TO CONTINUE WITH CONTENT

Get our best delivered to your inbox.

Mark those words: level of infection. As I said, it takes an epidemiologist to understand the impact of Trumpism on American institutions.

At the Border

It used to be difficult but not impossible to seek asylum at the border. Now, thanks to the Trump administration, its simply impossible.

If the desperate manage to get an interview, which itself is a major challenge, they meet with asylum officers. The Trump administration, arguing that people from south of the border in particular are lying about their cases, has tightened the eligibility requirements by adopting what it calls the Migration Protection Protocols (MPP).

Tightened the eligibility requirementsthats actually a euphemism. The Trump administration has violated international law by refusing asylum to those who face a risk of harm if theyre sent back to the country they left. Some asylum officers, according to This American Life, protested the new rules. They didnt get anywhere.

As reporter Molly OToole explains:

So the standard today is upside down from what it used to be under credible fear. Instead of, lets err on the side of letting people in because we dont want anyone to be tortured or die, under MPP the standard is almost impossibly high, so almost nobody gets in.

In numerical terms, it works out to about one in a thousand (11 out of 10,000, according to Syracuse University). In human terms, it means that every day, U.S. asylum officers are sending people directly into harms way. The use of the phrase concentration camp to describe detention facilities begins to sound grimly appropriate.

Trumps Willing Executioners

Such is the banality of evil. The problem lies not just in the upper echelons of the Trump administration setting the rules. Its everyone down the chain of command who is executing those policies.

True, some people are quitting. Others are blowing the whistle, as weve seen in the cases of the courageous few who testified in the House impeachment hearings. But they are the exceptions. The system continues to function.

Its not just ICE or Homeland Security. A cadre of federal employees at the Department of the Interior is currently opening up public lands to drilling. The Pentagon is expediting millions of dollars of weapons sales to one of the most despicable regimes on the planet, Saudi Arabia. Officials at USAID are enforcing the global gag rule by cutting off funding to organizations that provide access to reproductive health and family planning.

All across the country, tens of thousands of people are implementing the Trump administrations egregious policies. Of course, not everyone working for the federal government is involved in such crimes. Thousands and thousands of civil servants are maintaining programs that the Trump administration has yet to alter or close down that offer essential services or direct critical resources to individuals and communities in need.

But in a post-Trump future, whenever that day comes, how will we deal with the myriad willing executionersto quote Daniel Goldhagens book on the complicity of ordinary Germans in the Holocaust? The contagion spreads far beyond Trump, his cabinet, the Republicans on the Hill, and a few familiar faces in the media.

Compromised Immune System

Trumpism is an acute outbreak of a chronic disease. Americas body politic has been seriously compromised for years.

In Democracy in Chains, Nancy McLean chronicles the efforts by economist James M. Buchanan, the Koch brothers, and a raft of conservative foundations to systematically reduce the influence of the majority of citizens in politics. They have done so through a variety of mechanisms: privatizing federal programs that hitherto had majority support, challenging the power of unions, empowering states at the expense of the federal center.

She asks:

Is what we are dealing with merely a social movement of the right whose radical ideas must eventually face public scrutiny and rise or fall on their merits? Or is this the story of something quite different, something never before seen in American history? Could it beand I use these words quite hesitantly and carefullya fifth-column assault on American democratic governance?

The forces that have engineered this hostile take-over of Washington, D.C. never imagined that Donald Trump would lead their movement. Neither did conservative evangelicals or the NRA. They all expected someone more sober-minded, more calculating, more consistently ideological. Still, a useful idiot is a useful idiot.

Trumpism is what happens when a compromised immune system meets an unusual pathogen. America might be lucky enough to remove the proximate cause of infection through a victory at the polls. The top tier of Trump appointees can then be removed from office.

Unless we address the underlying susceptibility of the body politic to diseases of this nature, however, such outbreaks will continue flaring up for years to come. America faces a political pandemic unlike any in the last 200-plus years. To eradicate this kings disease the last time around, didnt we have to fight a revolution?

Originally posted here:
Americas Coronavirus: Containing the Outbreak of Trumpism - Common Dreams

Read More...

Virus has claimed more than 8,000 lives this season, but its not a new pandemic – CBS 4 Indianapolis

January 30th, 2020 3:42 pm

Please enable Javascript to watch this video

The novel coronavirusthat's sickening thousands globally -- andat least five people in the US-- is inspiring countries to close their borders and Americans tobuy up surgical masksquicker than major retailers can restock them.

There's another virus that has infected 15 million Americans across the country and killed more than 8,200 people this season alone. It's not a new pandemic -- it's influenza.

The 2019-2020 flu season is projected to beone of the worst in a decade, according to the National Institute of Allergy and Infectious Diseases. At least 140,000 people have been hospitalized with complications from the flu, and that number is predicted to climb as flu activity swirls.

The flu is a constant in Americans' lives. It's that familiarity that makes it more dangerous to underestimate, said Dr. Margot Savoy, chair of Family and Community Medicine at Temple University's Lewis Katz School of Medicine.

"Lumping all the viral illness we tend to catch in the winter sometimes makes us too comfortable thinking everything is 'just a bad cold,'" she said. "We underestimate how deadly influenza really is."

Even the low-end estimate of deaths each year is startling, Savoy said: The Centers for Disease Control predictsat least 12,000 people will die from the fluin the US every year. In the 2017-2018 flu season, as many as 61,000 people died, and 45 million were sickened.

In the 2019-2020 season so far, 15 million people in the US have gotten the flu and 8,200 people have died from it, including at least 54 children. Flu activity has been elevated for 11 weeks straight, the CDC reported, and will likely continue for the next several weeks.

Savoy, who also serves on the American Academy of Family Physician's board of directors, said the novelty of emerging infections can overshadow the flu. People are less panicked about the flu because healthcare providers "appear to have control" over the infection.

"We fear the unknown and we crave information about new and emerging infections," she said. "We can't quickly tell what is truly a threat and what isn't, so we begin to panic -- often when we don't need to."

Please enable Javascript to watch this video

Dr. Nathan Chomilo, an adjunct assistant professor of pediatrics at University of Minnesota Medical School, said that the commonness of the flu often underplays its severity, but people should take it seriously.

"Severe cases of the flu are not mild illnesses," Chomilo said. "Getting the actual flu, you are miserable."

The flu becomes dangerous when secondary infections emerge, the result of an already weakened immune system. Bacterial and viral infections compound the flu's symptoms. People with chronic illnesses are also at a heightened risk for flu complications.

Those complications include pneumonia, inflammation in the heart and brain and organ failure -- which, in some cases, can be fatal.

Chomilo, an internist and pediatrician for Park Nicollet Health Services, said this flu season has been one of the worst his Minnesota practice has seen since the H1N1 virus outbreak in 2009. Some of his patients, healthy adults in their 30s, have been sent to the Intensive Care Unit, relying on ventilators, due to flu complications.

Influenza is tricky because the virus changes every year. Sometimes, the dominant strain in a flu season will be more virulent than in previous years, which can impact the number of people infected and the severity of their symptoms.

Most of these changes in the virus are small and insignificant, a process called antigenic drift. That year's flu vaccine is mostly effective in protecting patients in spite of these small changes, said Melissa Nolan, an assistant professor at the University of South Carolina's School of Public Health.

Occasionally, the flu undergoes a rare antigenic shift, which results when a completely new strain of virus emerges that human bodies haven't experienced before, she said.

Savoy compares it to a block party: The body thinks it knows who -- or in this case, which virus -- will show up, and therefore, which virus it needs to keep out. But if a virus shows up in a completely new getup, it becomes difficult for the body's "bouncers" -- that's the immune system -- to know who to look for and keep out. The stealthy virus can infiltrate easily when the body doesn't recognize it.

This flu season, there's no sign of antigenic shift, the most extreme change. But it's happened before, most recently in 2009 with the H1N1 virus. It became a pandemic because people had no immunity against it, theCDC reported.

To avoid complications from the flu, Savoy, Chomilo and Nolan have the same recommendation: Get vaccinated.

It's not easy to tell how flu vaccination rates impact the number of people infected, but Savoy said it seems that the years she struggles to get her patients vaccinated are the years when more patients end up hospitalized with the flu, even if the total number of infections doesn't budge.

The CDC reported at least173 million flu vaccine doseshave been administered this flu season so far -- that's about 4 million more doses than the manufacturers who make the vaccines projected to provide this season.

Still, there are some who decide skipping the vaccine is worth the risk. A2017 studyfound that people decline the flu vaccine because they don't think it's effective or they're worried it's unsafe, even though CDCresearch showsthe vaccine effectively reduces the risk of flu in up to 60% of the population.

Chomilo said some of his most frustrating cases of the flu are in patients who can't be vaccinated because of preexisting conditions or their age (children under 6 months old can't be vaccinated).

There are two important reasons to get the flu vaccine, he said -- "Protecting yourself and being a good community member."

More here:
Virus has claimed more than 8,000 lives this season, but its not a new pandemic - CBS 4 Indianapolis

Read More...

Jacobs School names chair of Physiology and Biophysics – UB Now: News and views for UB faculty and staff – University at Buffalo Reporter

January 30th, 2020 3:42 pm

Mikhail V. Pletnikov has been named professor and chair of the Department of Physiology and Biophysics in the Jacobs School of Medicine and Biomedical Sciences at UB.

The appointment was announced by Michael Cain, vice president for health sciences and dean of the Jacobs School.

Dr. Pletnikov rapidly emerged as our top candidate possessing the administrative, scientific, leadership and visionary skills needed to move the department forward and further align the department with the Jacobs Schools strategic plans, Cain said in a statement.

Pletnikov, a native of Moscow, Russia, will relocate to Buffalo and join UB on July 1. He will be accompanied by his wife, Olga Pletnikova.

I feel honored to be appointed to this position, Pletnikov said. I am grateful to the members of the search committee, the faculty of the department and personally to Dr. Cain for placing their trust in me to lead the department. I look forward to working with the faculty, staff and students to support and promote education and biomedical research in the department and the school.

On a personal note, Olga and I are excited to move to Buffalo, he said. As for its weather, I am sure we will appreciate all four seasons there as, after all, we used to live in Moscow.

Pletnikov will succeed Perry Hogan, who has served as department chair since 2015.

Pletnikovs research focuses on understanding how neurons and non-neuronal cells (glial cells) interact with one another to support critical brain functions, including emotion and cognition. He also studies the mechanisms whereby the brain regulates functions of different organs in the body and itself is influenced by peripheral systems, particularly the immune system and the gut.

A growing number of studies suggest that abnormalities in these complex interactions lead to the development of disorders of the brain and peripheral organs, he said. Targeting cells, processes and pathways involved in the brain-periphery interplay is emerging as a new promising direction in treatment of complex brain disorders.

Pletnikovs research has been published in numerous journals. He lectures nationally and internationally, and serves on the editorial boards of leading scientific journals in his field, including Genes, Brains and Behavior; Biobehavioral Review; and Biological Psychiatry.

He received his doctorate in medicine from the I.M. Sechenov Moscow Medical Institute and his PhD in normal physiology from the PK Anokhin Institute of Normal Physiology in Moscow. He completed his postdoctoral training in behavioral neuroscience and neurovirology at Johns Hopkins University .

In 2000, Pletnikov joined the faculty at Johns Hopkins as an assistant professor and is currently a professor of psychiatry and behavioral sciences, neuroscience, and molecular and comparative pathology.

Read more from the original source:
Jacobs School names chair of Physiology and Biophysics - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter

Read More...

Page 725«..1020..724725726727..730740..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick